invIOs is developing NEXT-GENERATION CANCER THERAPEUTICS that empower and educate the immune system to fight cancer.
We leverage our DEEP EXPERTISE IN IMMUNE-SYSTEM ACTIVATION to advance a focused pipeline of individualized and targeted approaches against solid tumors.
All of our approaches are designed with a single goal: To TRANSFORM PATIENTS’ LIVES, so that cancer doesn’t.
OUR APPROACHES TO DEVELOPING NOVEL CANCER THERAPIES
- SMALL-MOLECULE PROGRAM to discover high-potential compounds
for tumor-specific immune activation and tumor cell killing - Innovative CELL-THERAPY PLATFORM (EPiC) for treating solid tumors,
with two disclosed assets
More about our SCIENCE
FOCUSED PIPELINE OF INNOVATIVE APPROACHES
INV501
- High-potential immune-activating small molecule
- Novel, orally available compound
- In pre-clinical development
APN401
- Tumor-reactive autologous cell therapy
- Highly-specific and targeted activation of white blood cells
- In Phase 1 trials against various solid tumors
INV441
- Tumor-associated cell therapy against glioblastoma multiforme
- Highly specific activation of tumor-infiltrating lymphocytes (TILs)
- In pre-clinical development
Learn more about our PIPELINE
SCIENCE NEVER SLEEPS
Read more of our NEWS
